JACC:SGLT-2I能明显降低患者死亡和心衰发生风险

2018-05-30 MedSci MedSci原创

既往研究显示钠葡萄糖共转运蛋白-2抑制剂(SGLT-2I)可以降低患者的死亡率和心衰发生率。本研究的目的旨在评估SGLT-2I对有心血管疾病(CVD)患者和无CVD患者的死亡率和心衰发生率的影响。本研究纳入了CVD-REAL临床研究中的2型糖尿病成年患者,并根据倾向性评分将患者分成SGLT-2I治疗组和其他降血糖药物(GLDs)。倾向性评分匹配后,每组各纳入了153078名患者,其中13%患者有C

既往研究显示钠葡萄糖共转运蛋白-2抑制剂(SGLT-2I)可以降低患者的死亡率和心衰发生率。本研究的目的旨在评估SGLT-2I对有心血管疾病(CVD)患者和无CVD患者的死亡率和心衰发生率的影响。

本研究纳入了CVD-REAL临床研究中的2型糖尿病成年患者,并根据倾向性评分将患者分成SGLT-2I治疗组和其他降血糖药物(GLDs)。倾向性评分匹配后,每组各纳入了153078名患者,其中13%患者有CVD。与GLDs治疗组相比,SGLT-2I治疗组中伴或不伴CVD患者的死亡风险均更低((HR: 0.56; 95% [CI]: 0.44-0.70; HR: 0.56; 95% CI: 0.50-0.63),心衰的发生率同样也更低(HR: 0.72; 95% CI: 0.63-0.82;  HR: 0.61; 95% CI: 0.48-0.78),心衰和死亡的复合发生风险也更低(HR: 0.63; 95% CI: 0.57-0.70; HR: 0.56; 95% CI: 0.50-0.62)。

本研究结果显示,无论有无基础心血管疾病,钠葡萄糖共转运蛋白-2抑制剂均能降低患者死亡和心衰的发生风险。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854046, encodeId=c02d185404693, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 22 11:59:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081975, encodeId=716420819e5f5, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Thu May 31 20:59:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983586, encodeId=57eb1983586d4, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 08 17:59:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793802, encodeId=35ee1e93802df, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Oct 20 04:59:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325848, encodeId=3464132584892, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448613, encodeId=c72d1448613b8, content=<a href='/topic/show?id=b374162192f' target=_blank style='color:#2F92EE;'>#SGLT-2i#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16219, encryptionId=b374162192f, topicName=SGLT-2i)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=lvygwyt2783, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319961, encodeId=326631996175, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Wed May 30 12:28:41 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
    2018-10-22 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854046, encodeId=c02d185404693, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 22 11:59:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081975, encodeId=716420819e5f5, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Thu May 31 20:59:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983586, encodeId=57eb1983586d4, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 08 17:59:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793802, encodeId=35ee1e93802df, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Oct 20 04:59:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325848, encodeId=3464132584892, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448613, encodeId=c72d1448613b8, content=<a href='/topic/show?id=b374162192f' target=_blank style='color:#2F92EE;'>#SGLT-2i#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16219, encryptionId=b374162192f, topicName=SGLT-2i)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=lvygwyt2783, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319961, encodeId=326631996175, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Wed May 30 12:28:41 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854046, encodeId=c02d185404693, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 22 11:59:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081975, encodeId=716420819e5f5, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Thu May 31 20:59:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983586, encodeId=57eb1983586d4, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 08 17:59:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793802, encodeId=35ee1e93802df, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Oct 20 04:59:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325848, encodeId=3464132584892, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448613, encodeId=c72d1448613b8, content=<a href='/topic/show?id=b374162192f' target=_blank style='color:#2F92EE;'>#SGLT-2i#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16219, encryptionId=b374162192f, topicName=SGLT-2i)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=lvygwyt2783, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319961, encodeId=326631996175, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Wed May 30 12:28:41 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854046, encodeId=c02d185404693, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 22 11:59:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081975, encodeId=716420819e5f5, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Thu May 31 20:59:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983586, encodeId=57eb1983586d4, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 08 17:59:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793802, encodeId=35ee1e93802df, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Oct 20 04:59:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325848, encodeId=3464132584892, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448613, encodeId=c72d1448613b8, content=<a href='/topic/show?id=b374162192f' target=_blank style='color:#2F92EE;'>#SGLT-2i#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16219, encryptionId=b374162192f, topicName=SGLT-2i)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=lvygwyt2783, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319961, encodeId=326631996175, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Wed May 30 12:28:41 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
    2018-10-20 tulenzi
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854046, encodeId=c02d185404693, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 22 11:59:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081975, encodeId=716420819e5f5, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Thu May 31 20:59:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983586, encodeId=57eb1983586d4, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 08 17:59:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793802, encodeId=35ee1e93802df, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Oct 20 04:59:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325848, encodeId=3464132584892, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448613, encodeId=c72d1448613b8, content=<a href='/topic/show?id=b374162192f' target=_blank style='color:#2F92EE;'>#SGLT-2i#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16219, encryptionId=b374162192f, topicName=SGLT-2i)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=lvygwyt2783, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319961, encodeId=326631996175, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Wed May 30 12:28:41 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1854046, encodeId=c02d185404693, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 22 11:59:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081975, encodeId=716420819e5f5, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Thu May 31 20:59:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983586, encodeId=57eb1983586d4, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 08 17:59:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793802, encodeId=35ee1e93802df, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Oct 20 04:59:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325848, encodeId=3464132584892, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448613, encodeId=c72d1448613b8, content=<a href='/topic/show?id=b374162192f' target=_blank style='color:#2F92EE;'>#SGLT-2i#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16219, encryptionId=b374162192f, topicName=SGLT-2i)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=lvygwyt2783, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319961, encodeId=326631996175, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Wed May 30 12:28:41 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1854046, encodeId=c02d185404693, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Oct 22 11:59:00 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081975, encodeId=716420819e5f5, content=<a href='/topic/show?id=acf116218e6' target=_blank style='color:#2F92EE;'>#SGLT-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16218, encryptionId=acf116218e6, topicName=SGLT-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a3a2500014, createdName=fmq_28614553, createdTime=Thu May 31 20:59:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1983586, encodeId=57eb1983586d4, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sat Dec 08 17:59:00 CST 2018, time=2018-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793802, encodeId=35ee1e93802df, content=<a href='/topic/show?id=5a3f1621e7d' target=_blank style='color:#2F92EE;'>#SGLT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16217, encryptionId=5a3f1621e7d, topicName=SGLT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Sat Oct 20 04:59:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325848, encodeId=3464132584892, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448613, encodeId=c72d1448613b8, content=<a href='/topic/show?id=b374162192f' target=_blank style='color:#2F92EE;'>#SGLT-2i#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16219, encryptionId=b374162192f, topicName=SGLT-2i)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=69885414022, createdName=lvygwyt2783, createdTime=Fri Jun 01 00:59:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=319961, encodeId=326631996175, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ac82155377, createdName=1201e5c5m39暂无昵称, createdTime=Wed May 30 12:28:41 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
    2018-05-30 1201e5c5m39暂无昵称

    学习了

    0

相关资讯

盘点:JACC5月第5期研究一览

1. 智能手表心律记录软件有助于房颤的筛查DOI: 10.1016/j.jacc.2018.03.003卡迪拉带(KB)是苹果手表中的一种可以记录患者心率和心律的技术,本研究的目的旨在评估KB能否准确辨别房颤患者的窦性心律(SR)。本研究纳入了100例房颤患者(年龄68 ± 11岁),在其进行复律之前接受了12导联心电图检查和KB记录,如果患者进行了复律治疗,则对其复律后的心电图和KB进行了记录,

JACC:受欢迎的维生素和矿物质补充剂没有提供健康益处

最近,来自多伦多大学的研究人员探究了补充维生素或微量元素对于心血管疾病的益处。

AGING CELL:社会压力使寿命缩短

这些数据突出了社会压力和低社会地位对缩短寿命和增加哺乳动物心血管疾病风险的保守作用,并确定了这种复杂现象的潜在机制。

JAHA:冠脉分叉病变单支架治疗的远期疗效研究

目前,对冠脉分叉病变的治疗是临时的单支架植入治疗而非双支架,该治疗方法由多中心随机对照试验的短期和中期结果支持,但其远期疗效如何尚未阐明。本次荟萃分析纳入了评估治疗冠脉分叉病变远期(>1年)疗效的临床随机对照试验,最终共纳入了来自9个临床随机对照试验的3265名患者,平均随访时间是3.1±1.8年。分析结果显示,单支架植入治疗与低的全因死亡率相关(2.94% vs 4.23%; RR: 0.69;

Eur J Gastroenterol Hepatol:患有非酒精性肝病的糖尿病患者,其心血管疾病的风险增加

这是独立于DM的影响,最先研究NAFLD与CVD之间关系的荟萃分析。研究结果表明,NAFLD增加了具有类似DM的人群的CVD的风险。诊断为NAFLD的糖尿病患者可能受益于更早期的心血管风险评估,从而降低心血管疾病的发病率和死亡率。

JAHA:社会隔离会增加心衰患者死亡风险!

感知型社会隔离对人体的健康有不良的影响。本研究的目的旨在评估心衰患者的感知型社会隔离对预后的影响。本研究纳入了2013年至2015年诊断的3867名心衰患者,对其感知型社会隔离程度进行了回顾评估,其中有2003名患者对问卷进行了反馈(反馈率52%),1681名患者(男性占53%,平均年龄为73岁)回答了所有的问题,并作为本次研究的对象。分析结果显示,有312名(19%)患者有中度的感知型社会隔离,